Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 28 X 40 mg |
|
Dosage
The recommended dose is 160 mg enzalutamide as a single oral daily dose.
Please refer to the license holder for further details.
Indications
* As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
*In combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC)
* For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).
* For the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failureof androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
* For the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.
Contra-Indications
* Hypersensitivity to the active substance or to any of the excipients
* Pregnant, or women of childbearing potential.
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.
